Serum C-reactive protein levels in normal-weight polycystic ovary syndrome

Korean Journal of Internal Medicine

Volumn 24, Issue 4, 2009, Pages 350-355

  Oh, Ji Young ^a   Lee, Ji Ah ^a   Lee, Hyejin ^a   Oh, Jee Young ^a   Sung, Yeon Ah ^a   Chung, Hyewon ^a  

^a Ewha Womans University School of Medicine   (South Korea)

Author keywords

C reactive protein; Cardiovascular disease; Polycystic ovary syndrome

Indexed keywords

C REACTIVE PROTEIN; GONADOTROPIN; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ADULT; ANTHROPOMETRY; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIASTOLIC BLOOD PRESSURE; FEMALE; GLUCOSE CLAMP TECHNIQUE; HUMAN; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; LEAN BODY WEIGHT; MENSTRUAL CYCLE; MULTIPLE REGRESSION; ORAL GLUCOSE TOLERANCE TEST; OVARY POLYCYSTIC DISEASE; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE;

ADULT; BODY MASS INDEX; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; POLYCYSTIC OVARY SYNDROME; REGRESSION ANALYSIS;

EID: 72049109689     PISSN: 12263303     EISSN: 20056648     Source Type: Journal    
DOI: 10.3904/kjim.2009.24.4.350     Document Type: Article

References (34)

1. Dunaif A, Thomas A. Current concepts in the polycystic ovary syndrome. Annu Rev Med 2001;52:401-419. (Pubitemid 32195332)
2. Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000;85:2434-2438. (Pubitemid 32269197)
3. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997;18:774-800. (Pubitemid 28009567)
4. Ciampelli M, Fulghesu AM, Cucinelli F, et al. Impact of insulin and body mass index on metabolic and endocrine variables in polycystic ovary syndrome. Metabolism 1999;48:167-172. (Pubitemid 29072269)
5. Franks S. Polycystic ovary syndrome. N Engl J Med 1995;333:853-861.
6. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in the polycystic ovary syndrome. Diabetes 1989;38:1165-1174. (Pubitemid 19250404)
7. Lovo RA, Goebelsmann U, Horton R. Evidence for the importance of peripheral tissue events in the development of hirsutism in polycystic ovary syndrome. J Clin Endocrinol Metab 1983;57:393-397.
8. Dunaif A. Insulin action in the polycystic ovary syndrome. Endocrinol Metab Clin North Am 1999;28:341-359. (Pubitemid 29242717)
9. Azziz R, Ehrmann D, Legro RS, et al. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab 2001;86:1626-1632. (Pubitemid 32374915)
10. Dahlgren E, Johansson S, Lindstedt G, et al. Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow up focusing on natural history and circulating hormones. Fertil Steril 1992;57:505-513.
11. Dahlgren E, Janson PO, Johansson S, Lapidus L, Oden A. Polycystic ovary syndrome and risk for myocardial infarction: evaluated from a risk factor model based on a prospective population study of women. Acta Obstet Gynecol Scand 1992;71:599-604. (Pubitemid 23050339)
12. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003;107:363-369. (Pubitemid 36158034)
13. Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metabol 2001;86:2453-2455. (Pubitemid 32545690)
14. Boulman N, Levy Y, Leiba R, et al. Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J Clin Endocrinol Metabol 2004;89:2160-2165. (Pubitemid 38619847)
15. Mohlig M, Spranger J, Osterhoff M, et al. The polycystic ovary syndrome per se is not associated with increased chronic inflammation. Eur J Endocrinol 2004;150:525-532. (Pubitemid 38584704)
16. Inoue S, Zimmet P, Caterson I, et al. The Asia-Pacific perspective: Redefining obesity and its treatment [Internet]. Sydney: Health Communications Australia Pty Ltd. 2000 [Cited 2009 August 20]. Available from: http://www.diabetes.com.au/pdf/obesity-report.pdf.
17. Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine F, eds. Polycystic Ovary Syndrome. Boston: Blackwell Scientific, 1992:377-384.
18. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:E214-E223. (Pubitemid 9249478)
19. Tsujimura A, Matsumiya K, Miyagawa Y, et al. Comparative study on evaluation methods for serum testosterone level for PADAM diagnosis. Int J Impot Res 2005;17:259-263. (Pubitemid 40675509)
20. Talbott EO, Zoborowski JV, Sutton-Tyrrell K, McHugh-Pemu KP, Guzick DS. Cardiovascular risk in women with polycystic ovary syndrome. Obstet Gynecol Clin North Am 2001;28:111-133. (Pubitemid 32242544)
21. Talbott E, Guzick D, Clerici A, et al. Coronary heart disease risk factor in women with polycystic ovary syndrome. Arterioscler Thromb Vasc Biol 1995;15:821-826.
22. Wild RA, Painter PC, Coulson PB, Carruth KB, Ranney GB. Lipoprotein lipid concentration and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1985;61:946-951.
23. Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol 2000;52:595-600. (Pubitemid 30337085)
24. Elting MW, Korsen TJ, Bezemer PD, Schoemaker J. Prevalence of diabetes mellitus, hypertension and cardiac complaints in a follow-up study of a Dutch PCOS population. Hum Reprod 2001;16:556-560. (Pubitemid 32218809)
25. Pierpoint T, McKeigue PM, Isaccs AJ, Wild SH, Jacobs HS. Mortality of women with polycystic ovary syndrome at long-term follow-up. J Clin Epidemiol 1998;51:581-586. (Pubitemid 28376967)
26. Gonzalez F, Thuse K, Abdel-Rahman E, Prabhala A, Tomani M, Dandona P. Elevated serum levels of tumor necrosis factor alpha in normal-weight women with polycystic ovary syndrome. Metabolism 1999;48:437-441. (Pubitemid 29174220)
27. Loverro G, Lorusso F, Mei L, Depalo R, Cormio G, Selvaggi L. The plasma homocystein levels are increased in polycystic ovary syndrome. Gynecol Obstet Invest 2002;53:157-162. (Pubitemid 34621637)
28. Sampson M, Kong C, Patel A, Unwin R, Jacobs HS. Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome. Clin Endocrinol 1996;45:623-629. (Pubitemid 26411365)
29. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular event. N Engl J Med 2002;347:1557-1565. (Pubitemid 35315836)
30. Aronson D, Bartha P, Zinder O, et al. Obesity is the major determinant of elevated C-reactive protein in subjects with metabolic syndrome. Int J Obes Relat Metab Disord 2004;28:674-679. (Pubitemid 38580975)
31. Lemieux I, Pascot A, Prud'homme D, et al. Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity. Arterioscler Thromb Vasc Biol 2001;21:961-967.
32. Albert MA, Glynn RJ, Buring J, Ridker PM. C-reactive protein levels among women of various ethnic groups living in the United States (from the Women's Health Study). Am J Cardiol 2004;93:1238-1242. (Pubitemid 38595677)
33. Saijo Y, Kiyota N, Kawasaki Y, et al. Relationship between C-reactive protein and visceral adipose tissue in healthy Japanese subjects. Diabetes Obes Metab 2004;6:249-258. (Pubitemid 38807798)
34. Pieroni L, Bastard JP, Piton A, Khalil L, Hainque B, Jardel C. Interpretation of circulating C-reactive protein levels in adults: body mass index and gender are a must. Diabetes Metab 2003;29:133-138. (Pubitemid 36576091)